• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ccRCC 细胞系的比较蛋白质组学分析以鉴定肾癌进展因子。

Comparative Proteomics of ccRCC Cell Lines to Identify Kidney Cancer Progression Factors.

机构信息

College of Pharmacy, Kyungpook National University, Daegu, Republic of Korea.

School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.

出版信息

Cancer Genomics Proteomics. 2024 Nov-Dec;21(6):645-652. doi: 10.21873/cgp.20480.

DOI:10.21873/cgp.20480
PMID:39467626
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11534031/
Abstract

BACKGROUND/AIM: Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer, accounting for approximately 75% of kidney cancers. The objective of this study was to identify novel progression markers for ccRCC based on proteomics, with the goal of stage determination and early diagnosis of kidney cancer patients.

MATERIALS AND METHODS

We performed quantitative global proteomics coupled with Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) and high-resolution tandem mass spectrometry on kidney-derived cells, including HEK-293, 786-O (primary ccRCC), and Caki-1 (metastatic ccRCC) cells, to investigate the novel progression factors of ccRCC.

RESULTS

In this study, a total of 1,106 proteins were quantified. The Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were conducted for differentially expressed proteins (DEPs) that were increased in ccRCC cells compared to HEK-293 cells. Ultimately, 99 DEPs including 75 up-regulated and 24 down-regulated proteins, that were significantly altered in both ccRCC cells, were identified. Among DEPs, vimentin was identified as the most significantly changed protein. Its increased expression in ccRCC was verified through immunoblotting in ccRCC cell lines and immunohistochemistry in kidney tumors.

CONCLUSION

From the global proteomics data detected in ccRCC, we propose 99 DEPs including vimentin as progression factors.

摘要

背景/目的：透明细胞肾细胞癌（ccRCC）是最常见的肾癌类型，约占肾癌的 75%。本研究旨在基于蛋白质组学鉴定 ccRCC 的新型进展标志物，以确定肾癌患者的分期和早期诊断。

材料和方法

我们对包括 HEK-293、786-O（原发性 ccRCC）和 Caki-1（转移性 ccRCC）在内的肾源性细胞进行了定量全局蛋白质组学和稳定同位素标记的氨基酸在细胞培养中的应用（SILAC）以及高分辨率串联质谱分析，以研究 ccRCC 的新型进展因子。

结果

在本研究中，共定量了 1106 种蛋白质。对与 HEK-293 细胞相比在 ccRCC 细胞中增加的差异表达蛋白（DEPs）进行了基因本体论和京都基因与基因组百科全书（KEGG）分析。最终，鉴定出 99 种 DEP，包括 75 种上调和 24 种下调蛋白，它们在两种 ccRCC 细胞中均发生明显改变。在 DEP 中，波形蛋白被鉴定为变化最显著的蛋白。通过 ccRCC 细胞系中的免疫印迹和肾脏肿瘤中的免疫组织化学验证了其在 ccRCC 中的高表达。

结论

从 ccRCC 检测到的全局蛋白质组学数据中，我们提出了包括波形蛋白在内的 99 种 DEP 作为进展因子。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18f4/11534031/6b6697894ac5/cgp-21-650-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18f4/11534031/7d5a2b8b2ec1/cgp-21-647-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18f4/11534031/739803723360/cgp-21-648-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18f4/11534031/6b6697894ac5/cgp-21-650-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18f4/11534031/7d5a2b8b2ec1/cgp-21-647-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18f4/11534031/739803723360/cgp-21-648-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18f4/11534031/6b6697894ac5/cgp-21-650-g0001.jpg

相似文献

1
Comparative Proteomics of ccRCC Cell Lines to Identify Kidney Cancer Progression Factors.ccRCC 细胞系的比较蛋白质组学分析以鉴定肾癌进展因子。
Cancer Genomics Proteomics. 2024 Nov-Dec;21(6):645-652. doi: 10.21873/cgp.20480.
2
Using Comparative Proteomics to Identify Protein Signatures in Clear Cell Renal Cell Carcinoma.应用比较蛋白质组学鉴定肾透明细胞癌的蛋白标志物。
Cancer Genomics Proteomics. 2023 Nov-Dec;20(6):592-601. doi: 10.21873/cgp.20408.
3
Hepatitis A virus cellular receptor 1/kidney injury molecule-1 is a susceptibility gene for clear cell renal cell carcinoma and hepatitis A virus cellular receptor/kidney injury molecule-1 ectodomain shedding a predictive biomarker of tumour progression.甲型肝炎病毒细胞受体 1/肾损伤分子 1 是透明细胞肾细胞癌的易感基因，甲型肝炎病毒细胞受体/肾损伤分子 1 外显子脱落是肿瘤进展的预测性生物标志物。
Eur J Cancer. 2013 May;49(8):2034-47. doi: 10.1016/j.ejca.2012.12.020. Epub 2013 Jan 23.
4
High-level S100A6 promotes metastasis and predicts the outcome of T1-T2 stage in clear cell renal cell carcinoma.高水平的S100A6促进透明细胞肾细胞癌的转移并预测T1-T2期的预后。
Cell Biochem Biophys. 2015 Jan;71(1):279-90. doi: 10.1007/s12013-014-0196-x.
5
Pan-cancer analysis and experiments with cell lines reveal that the slightly elevated expression of DLGAP5 is involved in clear cell renal cell carcinoma progression.泛癌症分析和细胞系实验表明，DLGAP5 的轻度升高表达与透明细胞肾细胞癌的进展有关。
Life Sci. 2021 Dec 15;287:120056. doi: 10.1016/j.lfs.2021.120056. Epub 2021 Oct 20.
6
Construction of circRNA-based ceRNA network to reveal the role of circRNAs in the progression and prognosis of metastatic clear cell renal cell carcinoma.构建基于 circRNA 的 ceRNA 网络，揭示 circRNAs 在转移性透明细胞肾细胞癌进展和预后中的作用。
Aging (Albany NY). 2020 Nov 20;12(23):24184-24207. doi: 10.18632/aging.104107.
7
Histology-guided proteomic analysis to investigate the molecular profiles of clear cell Renal Cell Carcinoma grades.组织学指导的蛋白质组学分析研究透明细胞肾细胞癌分级的分子特征。
J Proteomics. 2019 Jan 16;191:38-47. doi: 10.1016/j.jprot.2018.04.028. Epub 2018 Apr 23.
8
RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma.RAC2 可作为一种预后生物标志物，并促进肾透明细胞癌的进展。
Int J Oncol. 2019 Sep;55(3):645-656. doi: 10.3892/ijo.2019.4849. Epub 2019 Jul 26.
9
Quantitative proteomic analysis reveals potential diagnostic markers and pathways involved in pathogenesis of renal cell carcinoma.定量蛋白质组学分析揭示了肾细胞癌发病机制中潜在的诊断标志物和相关通路。
Oncotarget. 2014 Jan 30;5(2):506-18. doi: 10.18632/oncotarget.1529.
10
Ubiquitin-specific protease-44 inhibits the proliferation and migration of cells via inhibition of JNK pathway in clear cell renal cell carcinoma.泛素特异性蛋白酶-44 通过抑制 JNK 通路抑制肾透明细胞癌细胞的增殖和迁移。
BMC Cancer. 2020 Mar 12;20(1):214. doi: 10.1186/s12885-020-6713-y.

本文引用的文献

1
Cancer statistics, 2023.癌症统计数据，2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
2
Annexin A2 and Kidney Diseases.膜联蛋白A2与肾脏疾病
Front Cell Dev Biol. 2022 Sep 2;10:974381. doi: 10.3389/fcell.2022.974381. eCollection 2022.
3
The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences.PRIDE 数据库资源在 2022 年：一个基于质谱的蛋白质组学证据的中心。
Nucleic Acids Res. 2022 Jan 7;50(D1):D543-D552. doi: 10.1093/nar/gkab1038.
4
Challenges and opportunities in the proteomic characterization of clear cell renal cell carcinoma (ccRCC): A critical step towards the personalized care of renal cancers.在透明细胞肾细胞癌 (ccRCC) 的蛋白质组学特征分析中面临的挑战和机遇：迈向肾癌个体化治疗的关键步骤。
Semin Cancer Biol. 2019 Apr;55:8-15. doi: 10.1016/j.semcancer.2018.06.004. Epub 2018 Jul 25.
5
Choosing the right cell line for renal cell cancer research.为肾细胞癌研究选择合适的细胞系。
Mol Cancer. 2016 Dec 19;15(1):83. doi: 10.1186/s12943-016-0565-8.
6
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.美国癌症免疫治疗学会关于免疫治疗肾细胞癌的共识声明
J Immunother Cancer. 2016 Nov 15;4:81. doi: 10.1186/s40425-016-0180-7. eCollection 2016.
7
Vimentin Regulates Invasiveness and Is a Poor Prognostic Marker in Non-small Cell Lung Cancer.波形蛋白调节非小细胞肺癌的侵袭性且是不良预后标志物。
Anticancer Res. 2016 Apr;36(4):1545-51.
8
Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? Results of a comprehensive analysis based on the multicenter CORONA database.我们是否需要针对接受手术治疗的肾癌患者制定新的高风险标准，以改善未来辅助治疗临床试验的结果？基于多中心CORONA数据库的综合分析结果。
Eur J Surg Oncol. 2016 May;42(5):744-50. doi: 10.1016/j.ejso.2016.01.009. Epub 2016 Jan 22.
9
Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry.多机构前瞻性临床试验对小肾肿瘤延迟干预和监测的 5 年分析：DISSRM 登记处。
Eur Urol. 2015 Sep;68(3):408-15. doi: 10.1016/j.eururo.2015.02.001. Epub 2015 Feb 16.
10
EAU guidelines on renal cell carcinoma: 2014 update.EAU 指南：肾细胞癌. 2014 年更新版.
Eur Urol. 2015 May;67(5):913-24. doi: 10.1016/j.eururo.2015.01.005. Epub 2015 Jan 21.